Concord Biotech Ltd.
1,232.50
INR
-38.20
(-3.01%)
ISIN
INE338H01029
Return %
Stock
S&P 500
1Y
-18.52
14.39
3Y
6.42
81.42
5Y
- -
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Ankur Sudhir Vaid
- Full Time Employees
- 1,624
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 16th Floor, B-Wing Ahmedabad GJ India 380015
- IPO Date
- Aug 18, 2023
- Website
- concordbiotech.com
- Similar Companies
- Business
- Concord Biotech Limited, an India-based R&D-driven biopharmaceutical company founded in 1984 and headquartered in Ahmedabad, India, researches, develops, manufactures, markets, and sells fermentation-based active pharmaceutical ingredients, semi-synthetic APIs, and finished dosage formulations across immunosuppressants, anti-bacterial, oncology, anti-fungal, and other therapeutic segments to customers in over 70 countries including the USA, Europe, Japan, and India. The company offers immunosuppressants such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, pimecrolimus; oncology products including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix; anti-bacterials like mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin; anti-fungals comprising anidulafungin, caspofungin, micafungin sodium, amphotericin B, and nystatin; as well as other products such as lovastatin, pravastatin sodium, and enzymes; it also provides nephrology and critical care finished formulations along with contract research and manufacturing services in fermentation and semi-synthesis areas from three manufacturing facilities near Ahmedabad compliant with USFDA, EU-GMP, Japanese PMDA, and other global standards. In recent developments, Concord Biotech approved the acquisition of 100% equity in Celliimune Biotech in November 2025 to enter the cell and gene therapy segment and committed up to 100 million rupees to a solar power project for sustainability; the company secured key regulatory approvals including a USFDA Establishment Inspection Report and EU-GMP certification for its Dholka API facility, Russian GMP inspection completion at Dholka, NAFDAC approval for its Valthera oral solid dosage unit, and EU-GMP for its Limbasi facility, supporting expanded global market penetration amid strategic discussions with innovator firms for API supplies and second-source qualifications.